A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE Antibody Blinatumomab in Adult Subjects with Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (Alcantara Study)
Latest Information Update: 26 Jun 2023
At a glance
- Drugs Blinatumomab (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms Alcantara
- Sponsors Amgen
- 21 Jun 2023 According to an Amgen media release, Elias Jabbour, MD, Department of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston is the principal investigator of this trial.
- 15 Jun 2023 Results presented at the 28th Congress of the European Haematology Association
- 12 Feb 2021 Results of final analysis evaluating long term durability of responses to blinatumomab in patients with relapsed/refractory B-cell precursor acute lymphoblastic leukaemia, published in the European Journal of Cancer